

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Myopericarditis after vaccination, long COVID occurrence, BA.1 and BA.2 immune response in naïve and prior infected persons

Peer reviewed journals featured:

- A systematic review on myopericarditis after COVID-19 vaccination and non-COVID-19 vaccination [here](#) and associated commentary [here](#)
- Observational studies on:
 - Long COVID occurrence in COVID-19 survivors in Japan [here](#)
 - Risk of adverse events after COVID-19 in Danish children and adolescents and Comirnaty (Pfizer) effectiveness in adolescents [here](#)
 - Postmortem assessment of olfactory tissue degeneration and microvasculopathy in COVID-19 patients [here](#)
- Modelling studies on:
 - Screening, quarantine, and isolation strategies in Taiwan [here](#)
 - Dosing interval strategies for two-dose COVID-19 vaccination in 13 middle-income countries of Europe [here](#)

Letters and correspondence discussed:

- What comes next in the COVID-19 pandemic? [here](#)
- Incident rate ratios after booster vaccination [here](#)

Pre-peer review articles featured:

- Omicron BA.1 and BA.2 immune response in naïve and prior infected persons [here](#)
- SARS-CoV-2 reinfections with Omicron in fully vaccinated people in the northeast of Brazil [here](#)
- Effectiveness of 2 and 3 mRNA vaccine doses against Omicron and Delta infections in US outpatients [here](#)
- COVID-19 infection and vaccination responses to SARS-CoV-2 variants [here](#)
- Characteristics and outcomes of COVID-19 patients during Omicron dominance compared to Delta in 89 German hospitals [here](#)

Guidance and reports

- The National COVID-19 Clinical Evidence Taskforce released updated recommendations and clinical flowcharts [here](#)
- The Therapeutic Goods Administration (TGA) issued provisional approval to Pfizer for the use of COMIRNATY as a booster for aged 12–15 years old [here](#)

News and blogs

- Hospital and ambulance services struggle with huge demand and staff illness in England [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).